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Introduction  
 
In January 2020 Chinese researchers at the Wuhan Institute of Virology filed for a patent 
covering the use of remdesivir, an experimental antiviral drug, to treat COVID-19. Normally, 
this might be cause for celebration: COVID-19, a deadly pneumonia-like disease caused by 
the novel coronavirus, has killed so far thousands of people world-wide and sickened many 
more, sending researchers scrambling to develop an effective treatment.1 Only, the Wuhan 
Institute of Virology didn’t develop remdesivir. The drug was researched and produced by 
Gilead Sciences, a California-based pharmaceutical company, which had filed patent 
applications at several patent offices, including in China, covering a “method for treating 
Arenaviridae and coronaviridae virus infection”.2 
The remdesivir was originally developed to treat Ebola virus disease (EVD). From November 
2018 to August 2019, the drug underwent a Phase 3 experimentation trial.3 A relatively large 
sample of patients with EVD were treated with remdesivir, which appeared less effective than 
other drugs. However, in early 2020, scientists became suddenly interested in some studies 
indicating that Gilead’s product could have activity against coronaviruses like MERS and, 
hopefully, the rapidly spreading COVID-19.4 
The institute’s decision, made in the midst of a rapidly escalating health crisis, to claim rights 
over an unproven use of the drug was heavily criticized.5 It is worth noting that the Institute’s 
patent application was filed before scientists started experiments investigating the 
effectiveness of remdesivir against the COVID-19. In effect, the Wuhan Institute of Virology’s 
first in vitro studies suggesting that both remdesivir and an anti-malarial drug called 
chloroquine could effectively inhibit COVID-19 was published in early February 2020.6 
However, this study’s evidence depended on testing the efficacy of these drugs against 
                                               
1 Ye Roulin, “Wuhan’s Much-Maligned Virology Institute Seeks Patent on US Drug,” Sixth Tone, 
February 11, 2020, http://www.sixthtone.com/news/1005169/wuhans-much-maligned-virology-
institute-seeks-patent-on-us-drug. 
2 See Chinese patent application No CN108348526A, available at 
https://patents.google.com/patent/CN108348526A/en?oq=US2017071964. 
3 Sabue Mulangu et al., “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” New 
England Journal of Medicine 381, no. 24 (2019): 2293–2303, https://doi.org/10.1056/NEJMoa1910993. 
4 Timothy P. Sheahan et al., “Comparative Therapeutic Efficacy of Remdesivir and Combination 
Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV,” Nature Communications 11, no. 1 (2020): 
1–14, https://doi.org/10.1038/s41467-019-13940-6. 
5 Wu Haiyun, “China To Begin Testing Ebola Drug on Coronavirus Patients,” Sixth Tone, February 3, 
2020, http://www.sixthtone.com/news/1005155/china-to-begin-testing-ebola-drug-on-coronavirus-
patients. 
6 Manli Wang et al., “Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel 
Coronavirus (2019-NCoV) in Vitro,” Cell Research, 2020, 1–3, https://doi.org/10.1038/s41422-020-
0282-0. 
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another version of coronavirus, SARS-CoV-2. Earliest Phase 3 studies of remdesivir in 
COVID-19 infected patients started after the publication of that study.7 
Given the scale of the COVID-19 pandemic, one would expect a virology institute located at 
its original epicentre to devote its resources and energy to containing the spread of the 
underlying virus, or perhaps to researching new therapies and vaccines — not to patenting 
(supposedly new) uses for drugs it neither developed nor tested. Though legally admissible, 
the institute’s decision to seek a patent in this case is ethically questionable and may have a 
negative impact on China’s public health and medical research cooperation efforts. 
In response to the public outcry, the Wuhan Institute of Virology defended its patent application 
by claiming it was made in the national interest. It added that it would be willing to forgo 
enforcing its patent rights if foreign pharmaceutical companies — in this case, Gilead — 
collaborate with Chinese authorities to stop the pandemic.8 But this argument is weak. If the 
institute was really only concerned about public health and access to vital drugs in an 
emergency, there is already a mechanism that gives countries IP flexibility in just such an 
event: compulsory licenses. While controversial, compulsory licenses allow eligible 
drugmakers to legally manufacture and sell copycat versions of patented drugs during national 
emergencies, public health crises, or in other instances of extreme need. As a form of 
compensation for the original patent holder, the competent authority — in China’s case, it’d 
be the National Intellectual Property Administration — would require manufacturers to pay a 
“fair market price” for the drug.9  
Compulsory licences are explicitly allowed under Articles 48-50 of Chinese patent law, 
although the country has yet to issue one, and in line with the World Trade Organization’s 
TRIPS Agreement, which outlines global standards for protecting intellectual property (IP) 
rights. The 2001 Doha Declaration on the TRIPS Agreement and Public Health, adopted by 
the WTO Ministerial Conference, confirmed that compulsory licences can be used subject to 
certain conditions. And where they’ve been granted, they have led to significant reductions in 
drug prices. In 2012, for example, Indian generic drugmaker Natco was granted a compulsory 
licence for Sorafenib, an anticancer drug, after that country’s patent office ruled that Bayer 
AG, Sorafenib’s patent holder, had not done enough to make the drug available to Indian 
citizens. Natco was required to pay 6% royalties to the German company — a figure based 
                                               
7 https://clinicaltrials.gov/ct2/show/NCT04252664?term=remdesivir&draw=2&rank=2; 
https://clinicaltrials.gov/ct2/show/NCT04257656?term=remdesivir&draw=2&rank=1. 
8 Aaron Wininger, “Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir,” The 
National Law Review, February 6, 2020, https://www.natlawreview.com/article/wuhan-institute-virology-
applies-patent-gilead-s-remdesivir. 
9 See the webpage http://english.cnipa.gov.cn/ 
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on UN guidelines — and proposed selling its version for 97% off Bayer’s price.10  
Given the scale of the ongoing health crisis, a Chinese company filing for a compulsory licence 
would not necessarily be perceived as an attempt to unjustifiably circumvent Gilead’s patent 
rights. After all, in the wake of the coronavirus crisis, in March 2020 Israel has issued a 
compulsory licence in relation to Kaletra, an HIV medicine which is currently being tested for 
effectiveness in the treatment of Covid-19. The patent is owned by US pharmaceutical 
company Abbvie and the licence will allow Israel to import the generic version of Kaletra 
produced by the Indian company Hetero.11 Also, the Chilean parliament12 and Ecuador’s 
National Assembly13 have adopted resolutions that would pave the way for the issuance of 
compulsory licences to tackle the coronavirus outbreak; and the German government has 
started plans to limit patent rights in view of this pandemic.14 In North American, Canada is 
also following this lead.15 
The unusual strategy that the Wuhan Institute of Virology settled on — seeking to patent an 
untested use of a drug in such a way that it might interfere with patent rights owned by a 
foreign corporation — has raised hackles. Some critics have accused the institute of trying to 
get out of paying Gilead a licencing fee should a compulsory license be granted.16 Others have 
read its move as an attempt to secure bargaining chips in possible upcoming pricing 
negotiations with the company.17 
Another Chinese entity has come under fire from patent advocates. It’s Suzhou-based 
BrightGene Bio-Medical Technology, which may also be in for a fight after confirming that it 
had synthesized remdesivir’s active ingredient without first obtaining permission from the 
patent holder. Though the company says it’s interested in setting up a voluntary licensing 
                                               
10 Enrico Bonadio, Compulsory Licensing of Patents: The Bayer/Natco Case (2012) European 
Intellectual Property Review (Issue 10), pp. 719-728. 
11 Dani Kass, Israel Defies AbbVie IP To Import Generic Drugs For COVID-19, 19 March 2020, available 
at https://www.law360.com/articles/1255079/israel-defies-abbvie-ip-to-import-generic-drugs-for-covid-
19. 
12 See Resolution 896 adopted by the Chile Chamber of Deputies on 17 March 2020, available at 
https://www.keionline.org/chilean-covid-resolution. 
13 See the webpage https://www.keionline.org/32429. 
14 Thomas Musmann, German Government Plans Possibilities to Limit Patents In View of Corona 
Pandemic, 24 March (2020) Kluwer Patent Blog. 
15 Rory O’Neill, Canada Authorises Compulsory Licences for COVID-19, 27 March 2020, available at 
https://www.lifesciencesipreview.com/news/canada-authorises-compulsory-licences-for-covid-19-
shortfalls-3972. 
16 Joe McDonald – Linda A. Johnson, Chinese scientists ask for patent on US drug to fight virus, 6 
February 2020, ApNews, available at https://apnews.com/1fe943717b56b56cce5e733790f016dd. 
17 Susan Decker – Dong Lyu – Haze Fan, Gilead Declines on HIV Patent Fight Loss, China IP Interest, 5 
February 2020, available at https://www.bloomberg.com/news/articles/2020-02-05/gilead-declines-
after-hiv-patent-fight-loss-china-ip-interest. 
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agreement with Gilead at some point in the future, it also claims that its work hasn’t infringed 
that company’s patent rights because the final product is not being sold on the market.18 But 
this is highly debatable. Indeed, under both international and national patent laws, 
manufacturing a patented medicine, even if it’s not yet on sale, still amounts to patent 
infringement.19 
There are real risks to the strategies adopted by the Wuhan Institute of Virology and 
BrightGene. In particular, they may raise international companies’ suspicions regarding their 
Chinese peers. This in turn may hamper vital research cooperation between China and the 
world. Gilead, for example, has offered samples of remdesivir for use in clinical trials during 
the current outbreak. Other leading international pharmaceutical firms currently working on 
vaccines for COVID-19, like Johnson & Johnson and GlaxoSmithKline, may have less 
incentive to do so in the future if they believe China will not support their IP claims. A 
collaborative attitude has also been shown by AbbVie, which in March 2020 informed that due 
to current health emergency it would stop enforcing its patent anywhere in the world, also in 
relation to the treatment for HIV.20 
The Wuhan Institute of Virology and BrightGene are not the only entities which have been 
criticized. Gilead itself came under fire after its version of remdesivir obtained in March 2020 
the orphan drug designation from the US Food and Drug Administration. Under the US Orphan 
Drugs Act, such designation gives a seven-year market exclusivity period, as well as tax and 
other incentives for pharmaceutical companies which produce medicines for rare diseases 
that hit fewer than 200,000 people. Gilead was reprimanded for applying for such status and 
thus seeking exclusive rights “despite call for solidarity” to face the pandemic.21 After criticism, 
Gilead informed the public that it had requested to rescind the orphan drug designation.22 
As mentioned, one may argue that these behaviors are ethically questionable – and in 
particular that the patent system should not be used to make access to drugs more difficult, 
                                               
18 Angus Liu, Chinese firm copies Gilead’s remdesivir, the most promising drug against the new 
coronavirus, 12 February, available at https://www.fiercepharma.com/pharma-asia/chinese-firm-
copies-gilead-s-remdesivir-most-promising-drug-against-new-coronavirus. 
19 See for example Article 28 of the WTO TRIPS Agreement. 
20 Ellen ‘t Hoen, Covid-19 and the comeback of compulsory licensing, Medicines Law and Policy, 23 
March 2020, available at https://medicineslawandpolicy.org/2020/03/covid-19-and-the-come-back-of-
compulsory-licensing/. Donato Paolo Mancini, AbbVie drops patent rights for Kaletra antiviral treatment, 
23 March 2020 
21 Donato Paolo Mancini, Gilead criticised over ‘orphan status’ for potential virus treatment, Financial 
Times, 24 March 2020, available at https://www.ft.com/content/9fea4f1c-6dba-11ea-89df-
41bea055720b. 
22 See Gilead’s press release at https://www.gilead.com/-/media/gilead-corporate/files/pdfs/company-
statements/remdesivir-orphan-drug-
designation.pdf?la=en&hash=ED14BC7B26E2FEAA2E31E7741A8C9692. 
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especially during a pandemic. Can we really justify IP laws that are used in a way which limits 
the availability of medicines and aims at increasing profits in times of health emergency? This 
moment of crisis is teaching us a clear lesson in matter of philosophical justifications of IP: 
Egoistic theories are incapable of offering convincing arguments grounding IP protection.23 In 
effect, theories that consider personal gain (both in terms of existential self-realization24 or 
economic gain25) as the only legitimate source of an ethical defense of IP and as an 
overarching reason in cases of conflicts between individual and societal well-being appear 
untenable. The COVID-19 pandemic shows the essential interconnectedness of human 
beings as a community of unity, where individual happiness becomes possible only in cases 
where a certain level of welfare is collectively shared. 
In this sense, plausible justifications of IP protection must address the relationship between 
individual and collective needs and concerns. Utilitarianism does just that: It offers an 
argument in favor of IP that recognizes egoistic motives though within a larger altruistic 
framework, where societal utility functions as ultimate goal of our practices. Traditional 
versions of this argument suggest that incentives to authors and inventors are instrumental in 
maximizing social utility, which is the key principle of utilitarian ethical theories.26 In this sense, 
IP protection rewards innovators, who are then stimulated in investing more time in inventive 
and creative activities. This in turn is instrumental in obtaining conditions that are favorable for 
the occurrence of optimal social utility. Rewards are only justified in terms of the good that, 
indirectly, they bring to the whole of society. In this view, therefore, personal gain is simply a 
means to a higher purpose. Clearly, such utilitarian approach fits perfectly into the 
pharmaceutical industry’s incentive-focused narrative: “if patents for drugs aren’t available, 
research-and-development efforts will be discouraged”.   
Traditional forms of utilitarianism show limitations insofar they tend to identify innovators with 
individual subject (either persons, institutions, or companies). However, as efforts from the 
scientific community during this time of crisis clearly show, the process of discovery is often 
distributed and may very well profit from collaborations between different entities. In this 
                                               
23 For an instructive survey of philosophical justifications of intellectual property, see Adam Moore and 
Ken Himma, “Intellectual Property,” in The Stanford Encyclopedia of Philosophy, ed. Edward N. Zalta, 
Winter 2018 (Metaphysics Research Lab, Stanford University, 2018), 
https://plato.stanford.edu/archives/win2018/entries/intellectual-property/. 
24 Georg Wilhelm Friedrich Hegel, Elements of the Philosophy of Right, ed. Allen Wood (Cambridge: 
Cambridge University Press, 1991). 
25 John Locke, The Second Treatise of Government, ed. Peter Leslett (Cambridge: Cambridge 
University Press, 1988). 
26 Tom G. Palmer, “Are Patents and Copyrights Morally Justified - the Philosophy of Property Rights 
and Ideal Objects Symposium on Law and Philosophy,” Harvard Journal of Law & Public Policy 13, no. 
3 (1990): 817–66. 
www.city.ac.uk/law 
2020/07 
9 
 
sense, some innovators may very well be collective rather than individual subjects, and their 
activity should be protected. Therefore, among the less obvious implications of altruistic 
justifications of IP we have what follows: IP should establish favorable conditions for 
collaboration and exchange, and speeding up the process of scientific discovery. 
It is often difficult to balance these two opposing forces. The AIDS and HIV crisis of the 80s 
and 90s already showed us how patent laws may be used to oppose policies adopted by 
democratically elected governments to balance patent rights and make drugs more affordable. 
Indeed, in 1998 a group of pharmaceutical companies took the South African government to 
court to try to stop it introducing legislation aimed at reducing the price of medicines, the main 
objection being that the 1998 South African Medicines Act had arbitrarily reduced patent 
protection (the legal action was abandoned in 2001).27 
 
What these (old and recent) disputable behaviours teach us is that IP protection and in 
particular patent regimes must be managed with great care, as well as a willingness to 
occasionally set aside financial considerations in favour of ethical or moral concerns, 
especially when it comes to facing unprecedented global health emergencies like the COVID-
19 pandemic. While IP laws are certainly crucial as they incentivise the development of (often) 
vital drugs, they are far from perfect, and may very well require further adjustment or reform 
to meet overarching public interests. The solution is not to erode the mutual trust required to 
make international public health cooperation work. 
  
                                               
27 William W. Fisher III - Cyrill P. Rigamonti, The South Africa AIDS Controversy A Case Study in Patent 
Law and Policy (2005) Cyber Harvard, available at 
https://cyber.harvard.edu/people/tfisher/South%20Africa.pdf. 
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